The Potential of Exosomes Derived from Chronic Myelogenous Leukemia Cells As Biomarker Based on the BCR-ABL mRNA Transcript

被引：0
|
作者：
Kang, Ka-Won
Jung, Jikhan
Hur, Woojune
Park, Jaena
Shin, Hyunku
Choi, ByeongHyeon
Jeong, Hyesun
Kim, Dae Sik
Yu, Eun Sang
Lee, Se Ryeon
Sung, Hwa Jung
Kim, Seok Jin
Choi, Chul Won
Kim, Byung Soo
Kim, Hyun Koo
Hong, Sunghoi
Park, Ji-ho
Choi, Yeonho
Park, Yong
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2883
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy
    Akihiro Abe
    Yosuke Minami
    Fumihiko Hayakawa
    Kunio Kitamura
    Yuka Nomura
    Makoto Murata
    Akira Katsumi
    Hitoshi Kiyoi
    Catriona H. M. Jamieson
    Jean Y. J. Wang
    Tomoki Naoe
    International Journal of Hematology, 2008, 88 : 471 - 475
  • [22] Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy
    Abe, Akihiro
    Minami, Yosuke
    Hayakawa, Fumihiko
    Kitamura, Kunio
    Nomura, Yuka
    Murata, Makoto
    Katsumi, Akira
    Kiyoi, Hitoshi
    Jamieson, Catriona H. M.
    Wang, Jean Y. J.
    Naoe, Tomoki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (05) : 471 - 475
  • [23] Induction of BCR-ABL mutations for acquired resistance in chronic myelogenous leukemia cells by imatinib
    Yuan, Hongfeng
    Gao, Chunggang
    Bhatia, Ravi
    Chen, WenYong
    CANCER RESEARCH, 2009, 69
  • [24] RAS IS ESSENTIAL FOR TRANSFORMATION BY THE BCR-ABL ONCOGENE OF CHRONIC MYELOGENOUS LEUKEMIA
    SAWYERS, CL
    MCLAUGHLIN, J
    HAVLIK, M
    WITTE, O
    BLOOD, 1993, 82 (10) : A331 - A331
  • [25] BCR-ABL - AN ANTI-APOPTOSIS GENE IN CHRONIC MYELOGENOUS LEUKEMIA
    COTTER, TG
    LEUKEMIA & LYMPHOMA, 1995, 18 (3-4) : 231 - 236
  • [26] Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia
    O'Dwyer, ME
    Druker, BJ
    CURRENT OPINION IN ONCOLOGY, 2000, 12 (06) : 594 - 597
  • [27] Mechanism of stability and degradation of the chronic myelogenous leukemia oncoprotein, BCR-ABL
    Tsukahara, F
    Maru, Y
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 105P - 105P
  • [28] Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more
    Cea, M.
    Cagnetta, A.
    Garuti, A.
    Cirmena, G.
    Rocco, I.
    Moran, E.
    Grillo, V.
    Ballestrero, A.
    Patrone, F.
    Nencioni, A.
    JOURNAL OF BUON, 2009, 14 (04): : 565 - 573
  • [29] Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib
    Clapp, Geoffrey D.
    Lepoutre, Thomas
    El Cheikh, Raouf
    Bernard, Samuel
    Ruby, Jeremy
    Labussiere-Wallet, Helene
    Nicolini, Franck E.
    Levy, Doron
    CANCER RESEARCH, 2015, 75 (19) : 4053 - 4062
  • [30] Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification
    Pachmann, K
    Zhao, SR
    Schenk, T
    Kantarjian, H
    El-Naggar, AK
    Siciliano, MJ
    Guo, JQ
    Arlinghaus, RB
    Andreeff, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) : 749 - 759
12345